

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Weirton Medical Center</p> <p>2. 601 Colliers Way Weirton, West Virginia 26062-5091</p>	<p>In accordance with the letter dated October 2, 2015,</p> <p>3. License number 47-17567-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date January 31, 2024</p> <hr/> <p>5. Docket No. 030-12977</p>
---	---

- | | | |
|---|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Gadolinium 153</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (North American Scientific Model MED3601)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1.5 curies</p> <p>D. 25 microcuries</p> |
|---|--|---|

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
 - D. Possession and storage only incident to disposal.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 601 Colliers Way, Weirton, West Virginia.
- 11. The Radiation Safety Officer for this license is Mark T. Perna, M.S.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-17567-01

Docket or Reference Number
030-12977

Amendment No. 32

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
John J. DeFilippo, M.D.	35.100; 35.200; 35.300
Gary Loh, M.D.	35.100; 35.200; 35.300
Eric R. Balzano, M.D.	35.100; 35.200
Mark L. Benson, M.D.	35.100; 35.200
Vincent J. Caruso, M.D.	35.100; 35.200
Michael J. Maroney, M.D.	35.100; 35.200
Carter A. Kenamond, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Thomas Neis, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Michael L. Slaysman, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries
Eric William Irwin, M.D.	35.100; 35.200
James Andrew Epling, M.D.	35.100; 35.200
Kara Lynn Leslie, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine -131
John F. Balzano, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-17567-01

Docket or Reference Number
030-12977

Amendment No. 32

C. The following individuals are authorized users for non-medical uses as indicated:


Users

Material and Use

Mark T. Perna, M.S.

Gadolinium-153 in storage

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
16. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-17567-01

Docket or Reference Number
030-12977

Amendment No. 32

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- | | | |
|----|--------------------------------|---------------|
| A. | Application dated July 8, 2013 | [ML13203A101] |
| B. | Letter dated November 22, 2013 | [ML13347B037] |
| C. | Letter dated April 11, 2014 | [ML14113A024] |
| D. | Letter dated October 2, 2015 | [ML15287A216] |



For the U.S. Nuclear Regulatory Commission

Date November 18, 2015

By

Original signed by Shawn Seeley

Shawn Seeley
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406